Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. PHAR has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
PHAR stock price ended at $8.75 on Thursday, after losing-0.28%
The Pharming Group NV stock price decreased by -0.28% on the last trading day (01 May 2025), dropping from 8.3945 to 8.75. Throughout the last trading session, the stock experienced a fluctuation of 7.21% , ranging from a day low of $8.3945 to a day high of 9. The price has declined in 5 of the last 10 days, resulting in a total change of 8.16% during this period. On the last day, trading volume decrease by 238.00 shares, with the falling prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 2.39K shares were traded, amounting to approximately 21.35K.
PHAR Technical Signals
PHAR(Pharming Group NV Corp) has 4 buy signals and 3 sell signals now. The current trend is downtrend starting from 2025-02-18. The total price change during this trend is -7.46%. Recently, the price has decreased but the volume has also decreased, indicating a potential rebound signal. The average turnover of PHAR over the last 5 trading days is 14.32K. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
PHAR Moving Average Analysis
Pharming Group NV's overall moving average trend leans more bullish as of Friday, May 2, 2025, with 1 negative signals and 3 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $9.116700186000001, and $9.480088. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $7.940921814000001, and $7.577534000000002. A break-down below any of these levels will issue sell signals.
PHAR Short Selling Analysis
The short sale ratio of Pharming Group NV(PHAR) as of 30 Apr 2025 is 17.95%, rising from last trading day. With increasing price from 8.79 to 8.78. The short sell activity indicate that short sellers may be anticipating further declines.
Technical Signal
Technical Signals Summary
Neutral
Sell
3
Buy
4
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Positive
SMA_5 Above SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Positive
SMA_60 Above SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
4 Bullish Signals
4 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 > 0
0.274
Bullish
Momentum (10 days)
MOM_10 > 0
0.66
Bullish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 > 0
0.0789
Bullish
Moving Average
10-day SMA crosses above 250-day SMA
--
Bullish
3 Bearish Signals
3 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 > 80
89.158
Bearish
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 > 100
110.724
Bearish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 > 80
96.936
Bearish
PHAR Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Pharming Group NV(PHAR), our algorithm predicts PHAR's 1-month price at $10.56, with an 24.07%upwardshift. Using a similarity score up to 94.07%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Pharming Group NV (PHAR.O) stock, as of Sunday, April 27, 2025 , forecasts a 24.07% change over the next month, based on its high correlation with URG.A stock patterns. The similarity between their price movements over the analyzed periods is 94.07%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
PHAR
Future prediction
Up: 24.07%
URG
Up: 24.07%Similarity: 94.07%
Name
Similarity
Up/Down
URG.A
94.07%
+24.07%
EQIX.O
94.04%
+9.82%
TSEM.O
93.95%
-2.75%
CALM.O
93.69%
+0.43%
EDUC.O
93.56%
-9.09%
ARLO.N
93.53%
+1.71%
SSBI.O
93.49%
-3.56%
STWD.N
93.46%
+4.20%
ERII.O
93.45%
-8.25%
PARR.N
93.44%
+15.48%
PHAR Seasonality Analysis
Based on PHAR's historical stock price data across all years, the probability of a positive return in May is20.00%, suggesting it maynotbe an ideal month to invest in PHAR. In contrast,Januaryoffers the highest probability of positive returns at75.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Pharming Group NV (PHAR.O) stock in January has the highest probability of a positive return (75.00%), while February has the lowest probability (20.00%).
Performance Seasonality
The chart shows Pharming Group NV. (PHAR)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. PHAR has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Pharming Group NV (PHAR.O) stock in a year?
The radar chart shows that buying Pharming Group NV (PHAR.O) stock in January has the highest probability of a positive return (75.00%), while February has the lowest probability (20.00%).
How has Pharming Group NV. (PHAR)'s stock price performed over the past three years?
PHAR's stock price fell by -0.70% in 2023,decreased by -12.49% in 2024, and went down by 16.35% in 2025.
Is PHAR a buy based on overall technical signals summary?
PHAR has 4 buy signals and 3 sell signals now. Overall the technical rating for PHAR is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of PHAR.
What is the trend of Pharming Group NV (PHAR)'s moving average?
Pharming Group NV's overall moving average trend leans more bullish as of May 02 2025, with 1 negative signals and 3 positive signal.
What is price prediction for PHAR stock next month?
The price prediction chart for Pharming Group NV (PHAR.O) stock, as of April 27 2025, forecasts a 24.07% change over the next month, based on its high correlation with URG stock patterns. The similarity between their price movements over the analyzed periods is 94.07%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for PHAR Stock?
The price target for PHAR stock in 2025 is predicted to reach **$37**, driven by strong revenue growth from RUCONEST® and Joenja®. Analysts have set a **"Strong Buy"** rating with a 318.79% upside potential. The stock is expected to benefit from expanding market presence and pipeline expansion, including the acquisition of Abliva AB.
What is price prediction 2030 for PHAR Stock?
Pharming Group N.V. (PHAR) is expected to reach a stock price of **$15 to $20 by 2030**, driven by strong revenue growth from its core products, RUCONEST® and Joenja®, as well as its expanding pipeline in rare diseases. The company's 2024 revenue growth of 21% and its 2025 guidance of $315M to $335M highlight its momentum. Additionally, the acquisition of Abliva AB and the potential blockbuster drug KL1333 for mitochondrial diseases position PHAR for long-term growth.